Gynecological Cancer Drugs Market 2027 By Therapeutic Modality, Indication | The Insight Partners

Gynecological Cancer Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Therapeutic Modality (Chemotherapy, Targeted Therapy, Hormonal Therapy); Indication (Uterine Cancer, Ovarian Cancer, Vaginal and Vulvar Cancer, Cervical Cancer)

Report Code: TIPRE00007748 | No. of Pages: 151 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Gynecologic cancer is an uncontrolled growth and spread of abnormal cells that start from the reproductive organs. Furthermore, several factors responsible for the occurrence of gynecological cancer include infection from a virus known as HPV or human papillomavirus. Gynecological cancer can be treated with different medications, therapies, surgeries, or chemotherapy. The treatment of gynecological cancer depends upon the type and stage of cancer. Each gynecologic cancer is unique, with different signs and symptoms, various risk factors, and different prevention strategies.

MARKET DYNAMICS

The gynecological cancer drugs market is anticipated to grow in the market by factors such as an increase in the incidence of gynecological cancers, growth in importance of targeted drug therapies, public & private organizations for the development of novel drugs to treat cancer and increase in risk factors that lead to cancer. However, the high cost of drug development and the threat of failure & adverse effects of cancer drug therapy restrain the growth of the market. Moreover, the advancement of cancer drug research and the approach of personalized medicine are expected to drive the market during the forecast period.

MARKET SCOPE

The "Gynecological Cancer Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of in gynecological cancer drugs market with detailed market segmentation by therapeutic modality, indication and geography. The gynecological cancer drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading in gynecological cancer drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The gynecological cancer drugs market is segmented on the basis of therapeutic modality and indication. Based on therapeutic modality the market is segmented as chemotherapy, targeted therapy and hormonal therapy. On the basis of indication the market is categorized as uterine cancer, ovarian cancer, vaginal & vulvar cancer and cervical cancer.



Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the in gynecological cancer drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The gynecological cancer drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting gynecological cancer drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the gynecological cancer drugs market in these regions.




Get more information on this report :

MARKET PLAYERS


The report covers key developments in the in gynecological cancer drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from in gynecological cancer drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for in gynecological cancer drugs market in the global market. Below mentioned is the list of few companies engaged in the in gynecological cancer drugs market.

The report also includes the profiles of key in gynecological cancer drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Apotex Inc.
  •  AstraZeneca Plc
  •  Bristol-Myers Squibb Company
  •  Eli Lilly and Company
  •  F. Hoffmann-La Roche AG
  •  GlaxoSmithKline plc
  •  Merck & Co., Inc.
  •  Novartis AG
  •  Pfizer Inc.
  •  Teva Pharmaceutical Industries Ltd.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Gynecological Cancer Drugs Market - By Therapeutic Modality
1.3.2 Gynecological Cancer Drugs Market - By Indication
1.3.3 Gynecological Cancer Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GYNECOLOGICAL CANCER DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GYNECOLOGICAL CANCER DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. GYNECOLOGICAL CANCER DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. GYNECOLOGICAL CANCER DRUGS - GLOBAL MARKET OVERVIEW
6.2. GYNECOLOGICAL CANCER DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. GYNECOLOGICAL CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC MODALITY
7.1. OVERVIEW
7.2. THERAPEUTIC MODALITY MARKET FORECASTS AND ANALYSIS
7.3. CHEMOTHERAPY
7.3.1. Overview
7.3.2. Chemotherapy Market Forecast and Analysis
7.4. TARGETED THERAPY
7.4.1. Overview
7.4.2. Targeted Therapy Market Forecast and Analysis
7.5. HORMONAL THERAPY
7.5.1. Overview
7.5.2. Hormonal Therapy Market Forecast and Analysis
8. GYNECOLOGICAL CANCER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. UTERINE CANCER
8.3.1. Overview
8.3.2. Uterine Cancer Market Forecast and Analysis
8.4. OVARIAN CANCER
8.4.1. Overview
8.4.2. Ovarian Cancer Market Forecast and Analysis
8.5. VAGINAL AND VULVAR CANCER
8.5.1. Overview
8.5.2. Vaginal and Vulvar Cancer Market Forecast and Analysis
8.6. CERVICAL CANCER
8.6.1. Overview
8.6.2. Cervical Cancer Market Forecast and Analysis
9. GYNECOLOGICAL CANCER DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Gynecological Cancer Drugs Market Overview
9.1.2 North America Gynecological Cancer Drugs Market Forecasts and Analysis
9.1.3 North America Gynecological Cancer Drugs Market Forecasts and Analysis - By Therapeutic Modality
9.1.4 North America Gynecological Cancer Drugs Market Forecasts and Analysis - By Indication
9.1.5 North America Gynecological Cancer Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Gynecological Cancer Drugs Market
9.1.5.1.1 United States Gynecological Cancer Drugs Market by Therapeutic Modality
9.1.5.1.2 United States Gynecological Cancer Drugs Market by Indication
9.1.5.2 Canada Gynecological Cancer Drugs Market
9.1.5.2.1 Canada Gynecological Cancer Drugs Market by Therapeutic Modality
9.1.5.2.2 Canada Gynecological Cancer Drugs Market by Indication
9.1.5.3 Mexico Gynecological Cancer Drugs Market
9.1.5.3.1 Mexico Gynecological Cancer Drugs Market by Therapeutic Modality
9.1.5.3.2 Mexico Gynecological Cancer Drugs Market by Indication
9.2. EUROPE
9.2.1 Europe Gynecological Cancer Drugs Market Overview
9.2.2 Europe Gynecological Cancer Drugs Market Forecasts and Analysis
9.2.3 Europe Gynecological Cancer Drugs Market Forecasts and Analysis - By Therapeutic Modality
9.2.4 Europe Gynecological Cancer Drugs Market Forecasts and Analysis - By Indication
9.2.5 Europe Gynecological Cancer Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Gynecological Cancer Drugs Market
9.2.5.1.1 Germany Gynecological Cancer Drugs Market by Therapeutic Modality
9.2.5.1.2 Germany Gynecological Cancer Drugs Market by Indication
9.2.5.2 France Gynecological Cancer Drugs Market
9.2.5.2.1 France Gynecological Cancer Drugs Market by Therapeutic Modality
9.2.5.2.2 France Gynecological Cancer Drugs Market by Indication
9.2.5.3 Italy Gynecological Cancer Drugs Market
9.2.5.3.1 Italy Gynecological Cancer Drugs Market by Therapeutic Modality
9.2.5.3.2 Italy Gynecological Cancer Drugs Market by Indication
9.2.5.4 Spain Gynecological Cancer Drugs Market
9.2.5.4.1 Spain Gynecological Cancer Drugs Market by Therapeutic Modality
9.2.5.4.2 Spain Gynecological Cancer Drugs Market by Indication
9.2.5.5 United Kingdom Gynecological Cancer Drugs Market
9.2.5.5.1 United Kingdom Gynecological Cancer Drugs Market by Therapeutic Modality
9.2.5.5.2 United Kingdom Gynecological Cancer Drugs Market by Indication
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Gynecological Cancer Drugs Market Overview
9.3.2 Asia-Pacific Gynecological Cancer Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Gynecological Cancer Drugs Market Forecasts and Analysis - By Therapeutic Modality
9.3.4 Asia-Pacific Gynecological Cancer Drugs Market Forecasts and Analysis - By Indication
9.3.5 Asia-Pacific Gynecological Cancer Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Gynecological Cancer Drugs Market
9.3.5.1.1 Australia Gynecological Cancer Drugs Market by Therapeutic Modality
9.3.5.1.2 Australia Gynecological Cancer Drugs Market by Indication
9.3.5.2 China Gynecological Cancer Drugs Market
9.3.5.2.1 China Gynecological Cancer Drugs Market by Therapeutic Modality
9.3.5.2.2 China Gynecological Cancer Drugs Market by Indication
9.3.5.3 India Gynecological Cancer Drugs Market
9.3.5.3.1 India Gynecological Cancer Drugs Market by Therapeutic Modality
9.3.5.3.2 India Gynecological Cancer Drugs Market by Indication
9.3.5.4 Japan Gynecological Cancer Drugs Market
9.3.5.4.1 Japan Gynecological Cancer Drugs Market by Therapeutic Modality
9.3.5.4.2 Japan Gynecological Cancer Drugs Market by Indication
9.3.5.5 South Korea Gynecological Cancer Drugs Market
9.3.5.5.1 South Korea Gynecological Cancer Drugs Market by Therapeutic Modality
9.3.5.5.2 South Korea Gynecological Cancer Drugs Market by Indication
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Gynecological Cancer Drugs Market Overview
9.4.2 Middle East and Africa Gynecological Cancer Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Gynecological Cancer Drugs Market Forecasts and Analysis - By Therapeutic Modality
9.4.4 Middle East and Africa Gynecological Cancer Drugs Market Forecasts and Analysis - By Indication
9.4.5 Middle East and Africa Gynecological Cancer Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Gynecological Cancer Drugs Market
9.4.5.1.1 South Africa Gynecological Cancer Drugs Market by Therapeutic Modality
9.4.5.1.2 South Africa Gynecological Cancer Drugs Market by Indication
9.4.5.2 Saudi Arabia Gynecological Cancer Drugs Market
9.4.5.2.1 Saudi Arabia Gynecological Cancer Drugs Market by Therapeutic Modality
9.4.5.2.2 Saudi Arabia Gynecological Cancer Drugs Market by Indication
9.4.5.3 U.A.E Gynecological Cancer Drugs Market
9.4.5.3.1 U.A.E Gynecological Cancer Drugs Market by Therapeutic Modality
9.4.5.3.2 U.A.E Gynecological Cancer Drugs Market by Indication
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Gynecological Cancer Drugs Market Overview
9.5.2 South and Central America Gynecological Cancer Drugs Market Forecasts and Analysis
9.5.3 South and Central America Gynecological Cancer Drugs Market Forecasts and Analysis - By Therapeutic Modality
9.5.4 South and Central America Gynecological Cancer Drugs Market Forecasts and Analysis - By Indication
9.5.5 South and Central America Gynecological Cancer Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Gynecological Cancer Drugs Market
9.5.5.1.1 Brazil Gynecological Cancer Drugs Market by Therapeutic Modality
9.5.5.1.2 Brazil Gynecological Cancer Drugs Market by Indication
9.5.5.2 Argentina Gynecological Cancer Drugs Market
9.5.5.2.1 Argentina Gynecological Cancer Drugs Market by Therapeutic Modality
9.5.5.2.2 Argentina Gynecological Cancer Drugs Market by Indication
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. GYNECOLOGICAL CANCER DRUGS MARKET, KEY COMPANY PROFILES
11.1. APOTEX INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ASTRAZENECA PLC
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BRISTOL-MYERS SQUIBB COMPANY
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ELI LILLY AND COMPANY
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. F. HOFFMANN-LA ROCHE AG
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. GLAXOSMITHKLINE PLC
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. MERCK AND CO., INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. NOVARTIS AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. PFIZER INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Apotex Inc.
2. AstraZeneca Plc
3. Bristol-Myers Squibb Company
4. Eli Lilly and Company
5. F. Hoffmann-La Roche AG
6. GlaxoSmithKline plc
7. Merck & Co., Inc.
8. Novartis AG
9. Pfizer Inc.
10. Teva Pharmaceutical Industries Ltd.
TIPRE00007748
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking